Showing 2 of 10 years of data. Sign up free for 3 years, or upgrade for full access.
View Plans2-year trend showing gross, operating, and net profit margins
Natco Pharma Limited's net profit margin of 39.4% in FY2025 reflects excellent profitability, with operating margin at 48.4% and gross margin at 85.6%.
In FY 2025, Natco Pharma Limited posted a gross margin of 85.6%, an operating margin of 48.4%, a net margin of 39.4%. Gross Margin = (Revenue - COGS) / Revenue; Operating Margin = EBIT / Revenue; Net Margin = Net Income / Revenue. Typical healthy ranges: Gross 20-40%, Operating 10-20%, Net 5-10%+. Consistent or improving margins indicate strong competitive positioning.
2-year trend showing revenue, gross profit, and net profit
Natco Pharma Limited's revenue grew 15.9% to 47.84B and net profit grew 35.7% to 18.83B YoY in FY2025, indicating healthy business momentum.
In FY 2025, Natco Pharma Limited's revenue grew by 15.9% year-over-year. Revenue is total income from operations. Gross Profit is revenue minus cost of goods. Net Profit is the bottom line after all expenses. Consistent growth across all three signals a healthy, expanding business.
2-year trend showing shareholder returns
Natco Pharma Limited's ROE of 24.7% in FY2025 indicates excellent capital efficiency.
In FY 2025, Natco Pharma Limited reported an ROE of 24.7%. ROE = (Net Income / Shareholders' Equity) x 100. Measures how efficiently the company turns equity into profit. Above 15% is generally strong; above 25% is excellent. Very high ROE may signal high leverage — check alongside debt levels.
2-year trend comparing profitability with cash generation
Free Cash Flow = Operating Cash Flow - Capital Expenditure. When FCF exceeds net income, it suggests high-quality, cash-backed earnings. Persistent gaps may indicate aggressive accounting or heavy capex needs.
2-year trend comparing profitability with cash from operations
Operating Cash Flow is the actual cash from core operations. OCF exceeding net income signals strong cash collection. OCF trailing net income may indicate aggressive revenue recognition or working capital issues.
Measure a company's financial leverage, liquidity, and ability to meet financial obligations.
2-year trend showing short-term liquidity position
Natco Pharma Limited's current ratio of 5.59x in FY2025 indicates excessively high liquidity that may signal inefficient asset management.
In FY 2025, Natco Pharma Limited reported a current ratio of 5.59. Current Ratio = Current Assets / Current Liabilities. Measures short-term liquidity. A ratio of 1.5-3.0 is generally healthy; below 1.0 signals liquidity risk; above 3.0 may indicate underutilized assets.
2-year trend showing ability to service debt
Natco Pharma Limited's interest coverage ratio of 96.9x in FY2025 indicates comfortable debt servicing capacity.
In FY 2025, Natco Pharma Limited reported an interest coverage ratio of 96.9x. Interest Coverage = EBIT / Interest Expense. Shows how many times operating profit covers interest payments. Above 5x is comfortable; below 1.5x signals potential difficulty servicing debt.
2-year trend showing financial leverage and capital structure
Natco Pharma Limited's debt-to-equity ratio of 0.04x in FY2025 reflects a conservative, low-leverage capital structure.
In FY 2025, Natco Pharma Limited reported a debt-to-equity ratio of 0.04. Debt-to-Equity = Total Debt / Total Equity. Below 1.0 is conservative; 1.0-2.0 is moderate; above 2.0 indicates higher financial risk. Capital-intensive industries naturally carry higher ratios.
2-year trend showing total debt with year-over-year changes
Natco Pharma Limited's debt decreased 24.7% YoY in FY2025 — positive deleveraging improves financial flexibility.
In FY 2025, Natco Pharma Limited's total debt decreased by 24.7% year-over-year. Total Debt includes short-term debt, long-term loans, debentures, and capital leases. YoY changes (shown as percentages) reveal whether the company is leveraging up or deleveraging.
Year-over-year change in diluted shares outstanding
Natco Pharma Limited's diluted shares decreased 0.2% YoY in FY2025, indicating shareholder-friendly buybacks.
Over 2 years (FY2024–FY2025), diluted shares decreased 0.2% from 179.50M to 179.11M, reflecting long-term shareholder value creation.
In FY 2025, Natco Pharma Limited's diluted shares decreased by 0.2% year-over-year. Diluted Shares accounts for stock options, warrants, and convertibles. Positive YoY change means dilution (red); negative means buybacks (green). Consistent dilution above 5% annually is a red flag.
You're viewing 2 years of data. Upgrade to access 10 years of financial ratios, margins, and performance metrics.
Data from audited consolidated filings. For educational purposes only — not investment advice. Last update: FY 2025